Antibiotic duration and changes in FEV1 are not associated with time until next exacerbation in adult cystic fibrosis: a single center study

Table 2 Time until Next Exacerbation (TUNE) Univariable Models

Variable	Andersen-Gill		PWP-GT*
Variable	HR (95% CI)	p-value	HR (95% CI)	p-value
Age at baseline	0.97 (0.95–1.00)	0.03	0.98 (0.96–1.01)	0.19
BMI at baseline	0.99 (0.95–1.03)	0.52	0.99 (0.96–1.02)	0.61
FEV₁ at baseline	1 (0.96–1.03)	0.81	1 (0.99–1.00)	0.33
Male gender	0.75 (0.52–1.09)	0.13	0.86 (0.68–1.09)	0.20
CF-related diabetes	0.81 (0.48–1.37)	0.42	1.01 (0.7–1.46)	0.94
Duration of IV antibiotics	0.93 (0.98–1.02)	0.93	1.01 (0.99–1.02)	0.46
Absolute change (“drop”) in FEV₁ with onset of exacerbation	1 (0.99–1.01)	0.64	1 (0.98–1.01)	0.65
Absolute change (“recovery”) in FEV₁ with treatment	1.01 (0.99–1.03)	0.43	1 (0.98–1.02)	0.80
Recovery to 90% of baseline FEV₁	0.77 (0.53–1.11)	0.16	0.95 (0.73–1.23)	0.67

No final models were created for either method due to no more than a single co-variate reaching the p-value required for model entry
BMI body mass index, FEV ₁ forced expiratory volume in 1 s, CF cystic fibrosis, HR hazard ratio (95% confidence intervals reported in parentheses), PWP-GT Prentice, Williams and Peterson gap time

ISSN: 1471-2466